Trial Profile
A Phase II Study of Neovii Anti-human T-lymphocyte Immunoglobulin (ATLG, Grafalon®) With Post Transplant Escalated Doses of Post-transplant-Cyclophosphamide to Prevent Acute and Chronic GVHD Post Allogeneic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 27 Nov 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 27 Nov 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 16 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.